Product Description
Etonogestrel implant is used in women to prevent pregnancy. It is a form of birth control that contains a hormone in a flexible plastic rod about the size of a matchstick. It is effective for 3 years when inserted just beneath the skin of your upper arm. This medicine stops the release of an egg from your ovary. The mucus in your cervix thickens and may prevent sperm from reaching the egg. (Sourced from: https://www.mayoclinic.org/drugs-supplements/etonogestrel-intradermal-route/side-effects/drg-20069037?p=1)
Mechanisms of Action: ER Agonist,PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal,Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, Canada, Puerto Rico, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Contraception
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Implanon NXT | P1 |
Not yet recruiting |
Contraception |
2025-04-01 |
23% |
2025-03-20 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
| EVE-P6-604 | P1 |
Completed |
Contraception |
2023-12-11 |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
| MK-8415-060 | P3 |
Completed |
Contraception |
2024-12-30 |
41% |
2025-01-14 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/18/2025 |
News Article |
21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity |
|
05/01/2025 |
News Article |
Organon Reports Results for the First Quarter Ended March 31, 2025 |
|
04/09/2025 |
News Article |
Oxolife's CEO Agnès Arbat receives prestigious EU Women Innovators Prize |
|
02/13/2025 |
News Article |
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024 |